Uncovering the genomic regulatory network of myofibroblast differentiation in systemic sclerosis-associated interstitial lung disease
揭示系统性硬化症相关间质性肺疾病中肌成纤维细胞分化的基因组调控网络
基本信息
- 批准号:10688053
- 负责人:
- 金额:$ 16.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-08-31
- 项目状态:未结题
- 来源:
- 关键词:ATAC-seqAcute Respiratory Distress SyndromeAffectAutoimmuneAutoimmune DiseasesAutomobile DrivingBindingBinding SitesBiological AssayCause of DeathCell NucleusCellsChromatinClinicalComplexComputational BiologyCritical CareDNADNA BindingDataDepositionDevelopmentDiseaseEffector CellEnvironmentEpigenetic ProcessEtiologyExtracellular MatrixFibroblastsFibrosisFosteringGasesGenesGenetic TranscriptionGenomicsGoalsHumanHypersensitivityInterstitial Lung DiseasesInvestigationK-Series Research Career ProgramsKnowledgeLinkLungMedicineMentorsMolecular BiologyMyofibroblastPathogenesisPathogenicityPatientsPhenotypePhysiciansPopulationProcessProductionPublishingPulmonary FibrosisRUNX3 geneRegulationRegulator GenesRegulatory ElementResearchResearch ProposalsRheumatismRoleSamplingScientistSclerosisSourceStructure of parenchyma of lungSystemic SclerodermaTranscription Factor 3TransposaseUnited StatesUniversitiesWorkanalytical toolcareer developmentcell typedesigneffective therapyfibrotic lung diseasegain of functiongene regulatory networkgenome-wideimprovedleadership developmentmortalitymultiple omicsnovel therapeuticsnucleaseprofessorprogramssingle nucleus RNA-sequencingsingle-cell RNA sequencingskillsskin fibrosistherapeutic targettranscription factortranscriptometranscriptome sequencing
项目摘要
ABSTRACT
This application is for a Mentored Clinical Scientist Research Career Development Award entitled “Uncovering
the genomic regulatory network of myofibroblast differentiation in systemic sclerosis-associated interstitial lung
disease”, submitted by Dr. Eleanor Valenzi, an Assistant Professor of Medicine within the Division of Pulmonary,
Allergy and Critical Care Medicine at the University of Pittsburgh. The short-term goals detailed in this submission
are designed to help the applicant achieve her long-term objective of becoming an independent physician-
scientist and leader in the field of autoimmune interstitial lung disease (ILD) research. These short-term goals
include (1) advancing knowledge of computational and molecular biology (2) expansion of technical and analytic
tools to effectively perform translational ILD research, and (3) development of leadership skills to obtain
academic independence. This work will be completed in the Division of Pulmonary, Allergy and Critical Care
Medicine at the University of Pittsburgh, a rich research environment with a strong commitment to and proven
track record of fostering the development of physician-scientists. The central objective of this research proposal
is to investigate the gene regulatory networks driving myofibroblast differentiation in systemic sclerosis-
associated interstitial lung disease (SSc-ILD), as myofibroblasts are the key effector cell in fibrosis and no
treatments currently exist to target these cells. Interstitial lung disease is the leading cause of death in systemic
sclerosis, the rheumatic disease with the highest case mortality. The applicant’s prior published work identified
the transcriptome of the SSc-ILD pathogenic myofibroblasts in explanted lung tissues, however the specific gene
regulatory networks driving differentiation of resident fibroblasts to pathogenic myofibroblasts remain unknown.
Additional preliminary data implicates resident pulmonary fibroblasts as the primary source of myofibroblasts,
and the RUNX2/3 transcription factors (TFs) as putative positive regulators of myofibroblast differentiation. The
primary hypothesis is that RUNX2 and RUNX3, in association with specific composite motif TF partners, promote
myofibroblast differentiation and the aberrant myofibroblast phenotype in SSc-ILD. With this proposal, the
applicant will expand on her prior work with the following specific aims: (1) define the epigenetic and
transcriptional programs essential to myofibroblast differentiation, (2) reconstruct the regulatory network of
RUNX2/3 in myofibroblasts, and (3) determine the mechanism by which RUNX2/3 regulate the critical
myofibroblast effector functions of extracellular matrix expression and contractility. This proposal will determine
the SSc-ILD myofibroblast RUNX2/3 gene regulatory program and establish a pipeline for downstream
investigation of the critical implicated transcription factors and the mechanisms by which they regulate the
myofibroblast phenotype.
摘要
本申请是为指导临床科学家研究职业发展奖题为“发现
系统性硬化症肺间质成肌纤维细胞分化的基因调控网络
疾病”,由Eleanor Valenzi博士提交,他是肺科医学助理教授,
过敏和重症监护医学在匹兹堡大学。本文件中详细说明的短期目标
旨在帮助申请人实现成为独立医生的长期目标-
自身免疫性间质性肺病(ILD)研究领域的科学家和领导者。这些短期目标
包括(1)提高计算和分子生物学知识;(2)扩大技术和分析
工具,以有效地进行翻译ILD研究,和(3)发展领导技能,以获得
学术独立。这项工作将在肺、过敏和重症监护部门完成
医学在匹兹堡大学,一个丰富的研究环境与坚定的承诺,并证明
促进医生-科学家发展的良好记录。这项研究的主要目的是
是研究系统性硬化症中驱动肌成纤维细胞分化的基因调控网络-
相关间质性肺病(SSc-ILD),因为肌成纤维细胞是纤维化的关键效应细胞,
目前存在靶向这些细胞的治疗。间质性肺病是全身性疾病中死亡的主要原因。
硬化症是死亡率最高的风湿性疾病。申请人先前发表的作品
肺组织中SSc-ILD致病性肌成纤维细胞的转录组,然而,
驱动固有成纤维细胞分化为致病性肌成纤维细胞的调节网络仍然未知。
额外的初步数据表明,肺成纤维细胞是肌成纤维细胞的主要来源,
和RUNX 2/3转录因子(TF)作为肌成纤维细胞分化的假定正调节因子。的
主要假设是RUNX 2和RUNX 3与特定的复合基序TF配偶体相关,促进
肌成纤维细胞分化和SSc-ILD中异常肌成纤维细胞表型。根据这项建议,
申请人将扩展她以前的工作,具体目标如下:(1)定义表观遗传,
转录程序必不可少的肌成纤维细胞分化,(2)重建调控网络,
RUNX 2/3在肌成纤维细胞中的作用,以及(3)确定RUNX 2/3调节肌成纤维细胞中关键细胞的机制。
肌成纤维细胞效应子功能的细胞外基质表达和收缩性。该提案将决定
SSc-ILD肌成纤维细胞RUNX 2/3基因调控程序,并建立下游
研究关键的转录因子及其调控机制,
肌成纤维细胞表型
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Eleanor Valenzi其他文献
Eleanor Valenzi的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Eleanor Valenzi', 18)}}的其他基金
Uncovering the genomic regulatory network of myofibroblast differentiation in systemic sclerosis-associated interstitial lung disease
揭示系统性硬化症相关间质性肺疾病中肌成纤维细胞分化的基因组调控网络
- 批准号:
10523340 - 财政年份:2022
- 资助金额:
$ 16.11万 - 项目类别:
相似海外基金
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 16.11万 - 项目类别:
Research Grant
The Association Between Aging, Inflammation, and Clinical Outcomes in Acute Respiratory Distress Syndrome
衰老、炎症与急性呼吸窘迫综合征临床结果之间的关联
- 批准号:
10722669 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Sedatives Pharmacology in Acute Respiratory Distress Syndrome- SPA
急性呼吸窘迫综合征中的镇静药理学 - SPA
- 批准号:
491387 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Fellowship Programs
New mechanism-based TREM-1 therapy for acute respiratory distress syndrome
基于新机制的 TREM-1 疗法治疗急性呼吸窘迫综合征
- 批准号:
10678788 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Great Lakes Clinical Center of the Acute Respiratory Distress Syndrome, Pneumonia and Sepsis (APS) Consortium
急性呼吸窘迫综合征、肺炎和败血症 (APS) 联盟五大湖临床中心
- 批准号:
10646578 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Effect of ADAMTS13 on pathogenesis of acute respiratory distress syndrome
ADAMTS13 对急性呼吸窘迫综合征发病机制的影响
- 批准号:
23K08447 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A Novel Synthetic Biology-Derived Microbiome Therapeutic to Treat Viral-Induced Acute Respiratory Distress Syndrome (ARDS)
一种新型合成生物学衍生的微生物疗法,可治疗病毒引起的急性呼吸窘迫综合征(ARDS)
- 批准号:
10601865 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Development of drug therapy targeting ferroptosis, iron-dependent cell death for acute respiratory distress syndrome.
开发针对铁死亡(急性呼吸窘迫综合征的铁依赖性细胞死亡)的药物疗法。
- 批准号:
23K08360 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Sustainable Implementation of Prone Positioning for the Acute Respiratory Distress Syndrome
持续实施俯卧位治疗急性呼吸窘迫综合征
- 批准号:
10722194 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别:
Point-of-care system to assess the risk of trauma-induced acute respiratory distress syndrome
用于评估创伤引起的急性呼吸窘迫综合征风险的护理点系统
- 批准号:
10594793 - 财政年份:2023
- 资助金额:
$ 16.11万 - 项目类别: